Patent intelligence · US
US 10501511
Low molecular polypeptide for preventing and treating inflammation and use thereof
Low molecular polypeptide for preventing and treating inflammation and use thereof
Patent details — US 10501511
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 10, 2019
- Expiration
- Dec 5, 2039
- Applicant
- SHANGHAI FIRST PEOPLE'S HOSPITAL
- Claims
- 5
- CPC classes
- A61K, A61K38/00, A61K9/0014, A61K9/0019
Quick answer
US 10501511 (Low molecular polypeptide for preventing and treating inflammation and use thereof) is held by SHANGHAI FIRST PEOPLE'S HOSPITAL. Status: granted. Granted Dec 10, 2019. Expires Dec 5, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SHANGHAI FIRST PEOPLE'S HOSPITAL
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K38/00, A61K9/0014, A61K9/0019, A61K9/0048, A61P
More from SHANGHAI FIRST PEOPLE'S HOSPITAL
Related pharmaceutical patents in our USPTO index.
-
US 12357666
Traditional Chinese herbal plant composition for improving symptoms of liver cancer patients and compatibility method thereof
granted -
US 12228572
Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-infected cells
granted -
US 12220446
Use of upstream open reading frame 45aa-uORF nucleotide sequence of PTEN gene and polypeptide coded by 45aa-uORF
granted -
US 12090156
Application of CB-839 in preparation of drug for inhibiting corneal neovascularization (CNV)
granted -
US 12076443
Preparation method of nanozyme composite-based hybrid hydrogel eye drop
granted -
US 12016950
Devices and methods for treating ear pain
granted -
US 11992555
Solid solution compositions and use in chronic inflammation
granted -
US 11980602
Cannabinoid prodrug compounds
granted
Frequently asked questions
What is US patent 10501511?
US 10501511 (Low molecular polypeptide for preventing and treating inflammation and use thereof) is held by SHANGHAI FIRST PEOPLE'S HOSPITAL. Status: granted. Granted Dec 10, 2019. Expires Dec 5, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10501511?
SHANGHAI FIRST PEOPLE'S HOSPITAL is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 123 pharmaceutical patents for this assignee.
When does US 10501511 expire?
Our index shows an expiration date of Dec 5, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.